I have had a few emails and PMs asking about the use of Zydelig (idelalisib) for first line, since patients know I'm on this combined with rituxan.
I direct you to the newly revised drug label, which states...
1 INDICATIONS AND USAGE
1.1 Relapsed Chronic Lymphocytic Leukemia
Zydelig is indicated, in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (CLL) for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Limitation of Use
Zydelig is not indicated and is not recommended for first line treatment of patients with CLL.
Also note, that the black box warning have been just updated to include Fatal and serious infections...
I hope this answers some questions...